Moderna Inc. has announced the opening of the Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK. The new state-of-the-art manufacturing and R&D facility is now fully operational and will produce British-made mRNA vaccines to supply the UK population. The MITC can manufacture up to 100 million vaccine doses per year, with capacity to scale up to 250 million in a pandemic. The facility also houses laboratories to support global clinical trials and research into mRNA applications beyond respiratory diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077254) on September 24, 2025, and is solely responsible for the information contained therein.